A bold warning: the top FDA drug regulator is reportedly prepared to step away from the role just weeks after starting the job.
Democracy in the balance
Richard Pazdur, the agency’s premier figure overseeing cancer drugs and related evaluations, reportedly ran into friction with Trump administration officials over the legality and tempo of several initiatives. Although it’s possible he could rescind his resignation, insiders indicate that reversal is unlikely.
Updated
December 2, 2025 at 1:52 p.m. EST—breaking information
According to two individuals familiar with the matter who spoke on condition of anonymity due to personnel concerns, Pazdur has chosen to retire only a short time after assuming leadership of the FDA’s Center for Drug Evaluation and Research.
Additional context
Pazdur’s decision follows reported disagreements with interim leadership and political appointees about regulatory timing and authority. The question remains whether he will remain in the role or pursue retirement, as others around him weigh the potential implications for the FDA’s ongoing drug approval processes and strategic priorities.
What this means for readers and stakeholders
- Regulatory timelines could face changes as leadership transitions unfold.
- The situation highlights how political dynamics can influence scientific and clinical decision-making at the FDA.
- Stakeholders, including patients and industry, may be watching closely for signals about future drug review speed and policy directions.
Discussion prompt
What are your thoughts on how political pressures should influence independent drug regulation? Should senior officials stick with controversial policies for the sake of consistency, or step aside to avoid policy conflicts? Share your views in the comments.
